Abstract: TH-PO265
Measuring Quality of Life in Patients with CKD Anemia – SF36 and KDQOL
Session Information
- Anemia and Iron Metabolism: Clinical
October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 202 Anemia and Iron Metabolism: Clinical
Authors
- Pecoits-Filho, Roberto, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil
- Spinowitz, Bruce S., New York Hospital Medical Center of Queens, New Rochelle, New York, United States
- Pergola, Pablo E., Renal Associates, PA, San Antonio, Texas, United States
- Rochette, Samuel, Analysis Group, Inc., Montreal, Quebec, Canada
- Thompson-Leduc, Philippe, Analysis Group, Inc., Montreal, Quebec, Canada
- Lefebvre, Patrick, Analysis Group, Inc., Montreal, Quebec, Canada
- Bozas, Ana, Akebia Therapeutics, Inc., Cambridge, Massachusetts, United States
- Shafai, Gigi, Akebia Therapeutics, Inc., Cambridge, Massachusetts, United States
- Sanon, Myrlene, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States
- Krasa, Holly, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States
Background
Anemia of chronic kidney disease (CKD) has deleterious impacts on patients’ quality of life (QoL). The Standardized Outcomes in Nephrology (SONG) initiative identified QoL components as essential trial outcomes to be reported in hemodialysis and peritoneal dialysis-dependent (DD) patients. Resolving anemia of CKD may lead to more important QoL benefits in non-DD (NDD) patients than in DD patients (Eriksson 2016). QoL is frequently assessed using the 36-item general Short Form (SF-36) and the CKD-targeted Kidney Disease QoL (KDQoL), the latter being preferred in US dialysis clinics (Peipert 2017). It is unclear to which extent QoL tools are used to study anemia of CKD, and specifically in NDD patients. Therefore, we aimed to describe the evidence on treatments for anemia of CKD in which SF-36 and/or KDQoL were used, in both DD and NDD patients.
Methods
Studies included in a broader systematic literature review of treatments for anemia of CKD were reviewed. The Cochrane Library, MEDLINE, EMBASE, NHS EED, and NHS HTA were searched for English publications. Studies published between 1/1/2000-3/17/2017 meeting the following criteria were included: adult patients; focus is anemia of CKD; patients receiving iron, red blood cell transfusions, erythropoiesis-stimulating agents (ESA); results on QoL. Studies that used SF-36 or KDQoL were retained and qualitatively synthesized.
Results
1,625 publications were identified and 17 met the eligibility criteria. All studies focused on ESA, with or without iron replacement. SF-36 was used more frequently than KDQoL (11/17, 64.7%) across studies. Notably, KDQoL was used more frequently (vs. SF-36) in studies on DD patients (4 vs. 2) than in studies on NDD patients (1 vs. 8; 2 studies with mixed DD/NDD patients). Both tools showed QoL improvements (SF-36: 8/11, KDQoL: 4/6). QoL domains improved (e.g., vitality, physical/social functioning) and magnitude of results varied widely.
Conclusion
KDQoL was less frequently used in the NDD population than in DD patients (as expected, given CMS guidelines). Findings highlight how QoL treatment benefits are variable, and that there is a lack of standardized use of adapted QoL tools in studies of NDD patients.
Funding
- Commercial Support